A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
A legfontosabb adatok
- Ki végzi
- Epizyme, Inc.
- Hol
- Boston, Chattanooga, Denver, Hendersonville, Knoxville, Las Vegas, Nashville, New York, Pittsburgh, Port Saint Lucie, Rolling Meadows, San Antonio, San Diego, Syracuse és The Bronx (Egyesült Államok)Mind a 16 helyszín megnézéseMég 2 másik országban, 8 helyszínen
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1/2. fázis
- Résztvevők
- 102 fő vett részt
- Kezdés
- 2019. nov. 18.
- Befejezés
- 2024. nov. 4.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Tazemetostat
- Abiraterone/prednisone
- Enzalutamide
- A regiszteradat frissítve
- 2026. március 10.
- Miért állt le
- The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Age at the time of consent ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (Appendix
- Life expectancy of > 3 months
- Histologically or cytologically confirmed adenocarcinoma of the prostate. Small cell or neuroendocrine tumors of the prostate are also permitted
- Progressive disease in the setting of medical or surgical castration (ie, castration- resistant prostate cancer [CRPC]) by PCWG3 criteria for study entry; Evidence of disease progression by rising PSA or; Soft tissue progression per RECIST 1.1 or; Evidence of disease progression by observation of 2 new bone lesions since the initiation of last systemic therapy
- Metastatic prostate cancer disease, documented by the following imaging; Bone lesions on bone scan (per PCWG3) or by soft tissue disease (per RECIST 1.1) by CT/MRI imaging Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist
- Prior treatment with a second-generation androgen inhibitor as follows:; For phase 1b, EITHER Previously untreated with or progressed on a second generation androgen inhibitor (abiraterone, enzalutamide, or apalutamide) OR progressed on a second generation inhibitor (inhibitor (abiraterone, enzalutamide, or apalutamide); For phase 2 randomized component (i.e, enzalutamide- containing treatment arms) of the study, previously progressed on abiraterone
Ki nem vehet részt
- Treatment with any of the following for prostate cancer within the indicated timeframe prior to day 1 of starting study treatment:; First generation: AR antagonists (eg, bicalutamide, nilutamide, flutamide) within 4 weeks; 5-alpha-reductase inhibitors, ketoconazole, estrogens (including diethylstilbesterol), or progesterones within 2 weeks; Chemotherapy (except as permitted in inclusion criteria #10) within 3 weeks; Prior radionuclide therapy within 4 weeks; Another interventional product or standard agent in a clinical study within 28 days prior to the first planned dose of Tazemetostat; For phase 2 subjects to be randomized to one of the enzalutamide treatment arms only, prior treatment with the second-generation androgen antagonist including enzalutamide, apalutamide, darolutamide, and proxalutamide, etc
- Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for enrollment
- Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2
- Known symptomatic brain metastases
Helyszínek itt: Egyesült Államok
Még 2 másik országban, 8 helyszínen
- Beth Israel Deaconess Medical CenterBoston, Egyesült Államok
- Dana-Farber Cancer InstituteBoston, Egyesült Államok
- SCRI Tennessee Oncology ChattanoogaChattanooga, Egyesült Államok
- The Urology Center of ColoradoDenver, Egyesült Államok
- Urology Associates P.C.Hendersonville, Egyesült Államok
- XCancer - Tennesee Cancer SpecialistsKnoxville, Egyesült Államok
- Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, Egyesült Államok
- SCRI Tennessee Oncology - NashvilleNashville, Egyesült Államok
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült Államok
- University of Pittsburgh Medical Center - Hillman Cancer CenterPittsburgh, Egyesült Államok
- Hematology - Oncology Associates of the Treasure CoastPort Saint Lucie, Egyesült Államok
- XCancer - Northwest Oncology and HematologyRolling Meadows, Egyesült Államok
- Urology San AntonioSan Antonio, Egyesült Államok
- Genesis Healthcare PartnersSan Diego, Egyesült Államok
- Associated Medical Professionals of NY, PLLC - UrologySyracuse, Egyesült Államok
- Montefiore Einstein Center for Cancer CareThe Bronx, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC.
A teljes eredeti leírásKevesebb
This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.
A vizsgálat 4 csoportja
- Phase 1b: Tazemetostat in Combination with Abiraterone/PrednisoneA vizsgált kezelés
In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
Kezelés: Tazemetostat és Abiraterone/prednisone
- Phase 1b: Tazemetostat in Combination with EnzalutamideA vizsgált kezelés
In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
Kezelés: Tazemetostat és Enzalutamide
- Phase 2: Tazemetostat in Combination with EnzalutamideA vizsgált kezelés
Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone. All participants will receive treatment in 28-day cycles.
Kezelés: Tazemetostat és Enzalutamide
- Phase 2: Enzalutamide onlyMár használt kezelés, összehasonlításként
In Phase 2, Enzalutamide will be administered on cycle 1 day 1
Kezelés: Enzalutamide
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
- A regiszteradat frissítve
- 2026. március 10.